Tab. 1.
Antagonist | CCh | CaCl2 | ||
---|---|---|---|---|
| ||||
EC50 (M) | Emax ± S.E.M | EC50 (M) | Emax ± S.E.M | |
Control | 2.81×10−6 | 100 | 4.27×10−3 | 100 |
EOAH (ng/ml) | ||||
50 | 1.99×10−6 | 100 ± 5.32 | 6.55×10−3 | 64.5 ± 18.8 |
100 | 1.66×10−5 | 59.1 ± 7.72 | 8.16×10−3 | 59.1 ± 7.72 |
200 | 2.64×10−5 | 42.3 ± 4.35* | 1.15×10−2 | 42.3 ± 4.35* |
Papaverine (10−5 M) | 3.68×10−5 | 32.8 ± 2.06** | – | – |
Verapamil (10−6 M) | – | – | 1.13×10−2 | 46.6 ± 4.2** |
Number of experiments n = 6,
P < 0.05,
P < 0.01 statistically significant difference from control